Lewes, DE -- (SBWIRE) -- 08/09/2018 -- Acute Myeloid Leukemia - Market Insights, Epidemiology and Market Forecast-2027 report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Acute Myeloid Leukemia in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.

The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Acute Myeloid Leukemia from 2016 to 2027 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Geography Covered
- The United States
- EU5 (Germany, France, Italy, Spain and the United Kingdom)
- Japan

Study Period: 2016-2027

Acute Myeloid Leukemia - Disease Understanding and Treatment Algorithm
Acute Myeloid Leukemia (AML) is the fastest growing cancer that occurs when the bone marrow begins to make cells that have not yet completely matured also known as blasts. These blasts usually develops in the white blood cells. In AML, these cells do not develop and are unable to ward off infections. In Acute Myeloid Leukemia, bone marrow may also make abnormal red cells and platelets which increases rapidly, and the abnormal (leukemia) cells begin to crowd out the normal white blood cells, red blood cells and platelets that the body needs.

The Publisher Acute Myeloid Leukemia market report gives the thorough understanding of the Acute Myeloid Leukemia by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Acute Myeloid Leukemia in the US, Europe, and Japan.

Acute Myeloid Leukemia Epidemiology
The Acute Myeloid Leukemia epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Publisher report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology [segmented as Incident Cases, Age Specific Prevalence, Incidence of Relapsed/Refractory cases and Diagnosed population] scenario of Acute Myeloid Leukemia in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2016-2027.

As per American Cancer Society, approximately 19,520 new cases of Acute Myeloid Leukemia are estimated in 2018. Around 10,670 number of patients are expected to die due to Acute Myeloid Leukemia.

Acute Myeloid Leukemia Drug Chapters
This segment of the Acute Myeloid Leukemia report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

The typical treatments of AML involve chemotherapies which is divided into two phases i.e. induction and consolidation phase. Chemotherapy such as Cladribine, Topotecan, Etoposide, Methotrexate and Azacitidine are recommended for killing the cancer cells. The targeted therapies are used in case when chemo no longer responds.

Targeted therapy such as Enasidenib, Gemtuzumab and Midostaurin are recommended for treating Acute Myeloid Leukemia. Two promising therapies has recently entered the AML market; enasidenib (Idhifa) and liposomal cytarabine-daunorubicin CPX-351 (Vyxeos). Idhifa (enasidenib) is approved for the treatment of relapsed or refractory acute myeloid leukemia (AML) who have a specific genetic mutation by U.S. Food and Drug Administration (FDA).

Acute Myeloid Leukemia Market Outlook
The Acute Myeloid Leukemia market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

There are many potential candidates in the development phase for the treatment of Acute Myeloid Leukemia such as Gilteritinib by Astellas Pharma Inc., Pracinostat by Helsinn Healthcare S.A., OCV-501 and Guadecitabine (SGI-110) by Otsuka Pharmaceutical Co., Ltd., Iomab-B CD45 and Actimab-A (f.d.) CD33 by Actinium Pharmaceuticals, Inc., BST-236 by BioSight Ltd., etc. These drugs are expected to get launched in the study period from 2016-2027 and are going to create remarkable impact on Acute Myeloid Leukemia market.

Acute Myeloid Leukemia Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2016-2027. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Acute Myeloid Leukemia Report Insights
- Patient Population
- Therapeutic Approaches
- Pipeline Analysis
- Market Size and Trends
- Market Opportunities
- Impact of upcoming Therapies

Acute Myeloid Leukemia Report Key Strengths
- 10 Years Forecast
- 7MM Coverage
- Epidemiology Segmentation
- Sub-type Segmentation
- Key Cross Competition
- Highly Analyzed Market
- Drugs Uptake

Acute Myeloid Leukemia Report Assessment
- Current Treatment Practices
- Unmet Needs
- Pipeline Product Profiles
- Market Attractiveness
- Market Drivers and Barriers

Key Benefits
- This Publisher report will help to develop Business Strategies by understanding the trends shaping and driving Acute Myeloid Leukemia market
- Organize sales and marketing efforts by identifying the best opportunities for Acute Myeloid Leukemia market
- To understand the future market competition in the Acute Myeloid Leukemia market.

Spanning over 120 pages "Acute Myeloid Leukemia - Market Insights, Epidemiology and Market Forecast-2027" report covers Report Introduction, Acute Myeloid Leukemia (AML) Market Overview at a Glance, Disease Background and Overview, Epidemiology and Patient Population, Acute Myeloid Leukemia (AML) Geography wise Incident Cases, Marketed Drugs, Emerging Therapies, Market Size, 7MM Acute Myeloid Leukemia (AML): Market Analysis, Report Methodology.

Please visit this link for more details: https://www.marketresearchreports.com/delveinsight/acute-myeloid-leukemia-market-insights-epidemiology-and-market-forecast-2027

Find all Drug Pipeline Reports at: https://www.marketresearchreports.com/drug-pipeline

For related reports please visit: https://www.marketresearchreports.com/search/site/Acute%2520Myeloid%2520Leukemia

Read our Interactive Market Research Blog

About MarketResearchReprots.com
MarketResearchReprots.com is world's largest store offering quality market research, SWOT analysis, competitive intelligence and industry reports. We help Fortune 500 to Start-Ups with the latest market research reports on global & regional markets which comprise key industries, leading market players, new products and latest industry analysis & trends.

Contact us for your market research requirements: https://www.marketresearchreports.com/contact